This is a Phase I study designed to characterize the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous (s.c.) injection of pelacarsen in participants with mild hepatic impairment (HI) compared to matched healthy participants. This study will assess whether mild HI may affect the PK of pelacarsen.
Phase I study designed to characterize the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous (s.c.) injection of pelacarsen in participants with mild hepatic impairment (HI) compared to matched healthy participants. This study will assess whether mild HI may affect the PK of pelacarsen.